Certara, Inc. (NASDAQ:CERT) Given Average Rating of “Hold” by Analysts

Certara, Inc. (NASDAQ:CERT) has earned an average recommendation of “Hold” from the twelve analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $8.2778.

CERT has been the topic of several research analyst reports. Stephens cut their target price on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Robert W. Baird lowered their target price on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. Weiss Ratings raised Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. BMO Capital Markets reduced their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Finally, Morgan Stanley lowered their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th.

Certara Stock Performance

Shares of CERT stock opened at $8.35 on Monday. The business’s 50 day simple moving average is $7.37 and its 200 day simple moving average is $6.47. Certara has a one year low of $4.45 and a one year high of $13.88. The stock has a market capitalization of $1.27 billion, a PE ratio of -18.56 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same period last year, the company posted $0.07 EPS. The business’s revenue was down 10.8% compared to the same quarter last year. As a group, research analysts forecast that Certara will post 0.22 earnings per share for the current year.

Institutional Investors Weigh In On Certara

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. raised its stake in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Certara during the second quarter worth approximately $83,000. Finally, Gamco Investors INC. ET AL bought a new position in shares of Certara in the 4th quarter worth $90,000. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.